* 中国生物科技公司--乐普生物2157.HK周三早盘一度劲升10.2%，创1月26日以来新高，早市收涨1.7%。
* 该公司此前公告称，持股30%的合营企业获阿斯利康AZN.L支付4,500万美元里程碑付款，因该合营企业授权给阿斯利康的药物AZD0901启动三期临床试验。
这个试验是：AZD0901联合卡培他滨联合或不联合rilvegostomig一线治疗Claudin 18.2阳性、HER2阴性的晚期╱转移性胃癌、胃食管结合部癌或食管腺癌的多中心、随机对照、III期临床研究。已经完成了首例受试者给药。
* 乐普生物今年迄今跌3.6%，同期恒生指数.HSI上扬1.4%。
* 恒⽣⽣物科技指数.HSBIO早盘收低0.9%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 田镧沁)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.